Form 4: Cyclacel 10% Owner Sells Shares, Exits Section 16

A 10% owner and director of Cyclacel Pharmaceuticals, David E. Lazar, sold 6,750 shares of common stock and is no longer subject to Section 16 reporting requirements.

Summary

• David E. Lazar, a Director and 10% owner of Cyclacel Pharmaceuticals, Inc. (CYCC), sold 6,750 shares of common stock.
• The sale occurred on July 30, 2025, at a price of $12.36 per share.
• Following this transaction, Lazar beneficially owns 155,838 shares of common stock.
• The number of shares owned reflects a 1-for-15 reverse stock split effected by Cyclacel on July 7, 2025.
• This filing serves as an exit filing, indicating Lazar is no longer subject to Section 16 of the Exchange Act due to this sale.
• A previous Form 4 filed on February 28, 2025, contained a ministerial error, inadvertently reporting 354,738 shares of Series D Convertible Preferred Stock which had already converted into 162,588 shares of Common Stock (after giving effect to the Reverse Stock Split) as of that date.

Sentiment

Score: 3

Explanation: The sale of shares by a significant insider (10% owner and director) and their subsequent exit from Section 16 reporting is generally viewed negatively by the market, as it can signal a lack of confidence or a shift in strategic interest. The correction of a previous reporting error is a minor positive for data accuracy but doesn't offset the sentiment impact of the sale.

Negatives

• A 10% owner and director, David E. Lazar, sold 6,750 shares of common stock, which could be interpreted negatively by investors as a reduction in insider ownership.
• The filing indicates an "exit filing," meaning the reporting person is no longer subject to Section 16, suggesting a significant reduction in their stake or influence, or a complete divestment of their reporting obligation.

Risks

• Potential negative investor sentiment due to a significant insider sale by a 10% owner and director.
• Risk of misinterpretation of past filings due to previously reported "inadvertent ministerial error" regarding beneficial ownership.

Future Outlook

NA

Industry Context

This Form 4 filing details an insider transaction, which is a routine disclosure for publicly traded companies. It does not provide broader industry context or trends, focusing solely on the individual's stock activity within Cyclacel Pharmaceuticals, a company in the pharmaceutical sector.

Stakeholder Impact

• Shareholders: May interpret the insider sale as a negative signal, potentially leading to decreased confidence or selling pressure on the stock.

Key Dates

Recommendation

While the sale by a 10% owner and director could be seen as a negative signal, the transaction volume (6,750 shares) is relatively small compared to the remaining beneficial ownership (155,838 shares) and the company's overall float. The primary impact is the reporting person no longer being subject to Section 16, which reduces transparency on future insider activity from this individual. Given the limited information in a Form 4, a 'hold' recommendation is prudent, advising investors to monitor future company developments and broader market trends rather than making a definitive buy/sell decision solely based on this insider transaction.

Keywords

Cyclacel Pharmaceuticals, CYCC, SEC Form 4, Insider Trading, Stock Sale, David E. Lazar, Reverse Stock Split, Beneficial Ownership, Director Sale, 10% Owner